Ann: Financial Results for the Half Year to 30 September 2023, page-7

EYE just had the final LCD for its product completely withdrawn resulting in about a 100% share price gain the past few days. Not quite back to where it was pre-LCD, and definitely not yet accounting for significant progress made over that period, but it is close enough to be quite happy. I see similar flaws with the LCD facing PEB so I'm quite interested... I agree with posters here that this LCD will likely be scrapped (IMO of course)

Seems like the same case here of medicare not wanting to fund a popular procedure/test. This is completely backwards as they are popular because they are effective for patients, and hence should be covered. In the case of EYE, it seems what helped the most with overcoming the LCD was not necessarily the evidence presented but the push back against it from medical associations, doctors, patients, politicians etc.

All the best to holders here, I will be watching how this progresses quite closely. Very frustrating when insurers try to tell doctors what they should and shouldn't do